October 22-26, 2025
Hynes Convention Center
Boston, Massachusetts

Abstract Submission Deadline (Opening Soon): Monday, July 21, 2025, 1 p.m. ET

Late-breaking and Clinical Trial Abstract Submission Available: Wednesday, August 27- Wednesday, September 10, 2025, 1 p.m. ET

sign up to request additional information

Scientific Committee Cochairs

Ryan B. Corcoran, Massachusetts General Hospital, Boston, Massachusetts (AACR)
Tim F. Greten, National Cancer Institute, Bethesda, Maryland (NCI) 
Elena Garralda, Vall d’Hebron Institute of Oncology, Barcelona, Spain (EORTC) 

Organizing Committee Cochairs

Patricia M. LoRusso, Yale Cancer Center, New Haven, Connecticut (AACR)
James H. Doroshow, National Cancer Institute, Bethesda, Maryland (NCI)
Denis A. Lacombe, European Organisation for Research and Treatment of Cancer, Brussels, Belgium (EORTC)

Hosted by the American Association for Cancer Research, the National Cancer Institute, and the European Organisation for Research and Treatment of Cancer, the 2025 Molecular Targets and Cancer Therapeutics conference will once again attract 1,500-2,000 academics, scientists, regulatory agency staff, investors, and biotech and pharmaceutical industry representatives from across the globe to discuss innovations in drug development, target selection, the impact of new discoveries in cellular and molecular biology, and early clinical trials. 

Innovative, targeted therapeutics are discovered through the rapid advances in our understanding of the molecular basis of cancer. Continued clinical progress in cancer treatments is accomplished through the conduct of translational research projects, efficient new drug development, and the execution of large, prospective, randomized, multicenter cancer clinical trials. This requires a joint and global approach and exchange of information early in the development process.

Scientific Committee Members:

Rosemarie Aurigemma, NIH-NCI, Rockville, Maryland
Nilofer S. Azad, Johns Hopkins University, Baltimore, Maryland*
Udai Banerji, The Institute of Cancer Research, London, United Kingdom
Bristi Basu, University of Cambridge, Cambridge, United Kingdom
Philippe L. Bedard, University Health Network, Toronto, Ontario, Canada
Johanna Bendell, F. Hoffmann-La Roche Ltd., Basel, Switzerland
Alice P. Chen, National Cancer Institute, Bethesda, Maryland
Raffaele Colombo, Zymeworks, Inc., Vancouver, British Columbia, Canada
Natalie Cook, The Christie NHS Foundation Trust, University of Manchester, Manchester, United Kingdom
Benjamin F. Cravatt, The Scripps Research Institute, San Diego, California
Giuseppe Curigliano, European Institute of Oncology, Milan, Italy
E.G. Elisabeth de Vries, University Medical Center Groningen, Groningen, Netherlands*
Jaydira Del Rivero, National Cancer Institute, Bethesda, Maryland*
James H. Doroshow, NCI Division of Cancer Treatment and Diagnosis, Bethesda, Maryland
Alexander Drilon, Memorial Sloan Kettering Cancer Center, New York, New York*
Ecaterina E. Dumbrava, The University of Texas MD Anderson Cancer Center, Houston, Texas
Anna Farago, Amgen Oncology, Newton, Massachusetts
Elena Garralda, VHIO Vall D’Hebron Institute of Oncology, Barcelona, Spain
Steven D. Gore, National Institutes of Health, Baltimore, Maryland
Lyndsay N. Harris, National Cancer Institute, Rockville, Maryland
Sara A. Hurvitz, Fred Hutchinson Cancer Center, Seattle, Washington
S. Percy Ivy, National Cancer Institute, Bethesda, Maryland
Katrina L. Jackson, C4 Therapeutics, Watertown, Massachusetts
Peng Jiang, National Cancer Institute, Bethesda, Maryland
Melissa L. Johnson, Sarah Cannon Research Institute, Nashville, Tennessee 
Stephen Kelsey, Revolution Medicines, Redwood City, California
Jung-Min Lee, National Cancer Institute, Bethesda, Maryland
Christophe Massard, Gustave Roussy, Rennes, France
Victor Moreno, START Madrid, Madrid, Spain
Ralph E. Parchment, NCI-Frederick/Leidos Biomedical Research, Inc., Frederick, Maryland
Lilli Petruzzelli, Genentech, Inc., San Francisco, California
Yves G. Pommier, National Cancer Institute, Bethesda, Maryland
Victoria Sanchez, VHIO Vall D’Hebron Institute of Oncology, Barcelona, Spain
John Schneekloth, National Cancer Institute, Frederick, Maryland
Patrick Schöffski, Catholic University of Leuven, Leuven Cancer Institute, Leuven, Belgium
Alison Schram, Memorial Sloan Kettering Cancer Center, Scarsdale, New York
Lesley K. Seymour, Queen’s University, Kingston, Ontario, Canada
Alexander Spira, Virginia Cancer Specialists, Herndon, Virginia
Neeltje Steeghs, Netherlands Cancer Institute, Amsterdam, Netherlands
Vivek Subbiah, Sarah Cannon Research Institute, Nashville, Tennessee
Stefan N. Symeonides, University of Edinburgh, Edinburgh, United Kingdom*
Beverly A. Teicher, National Cancer Institute, Rockville, Maryland
Craig Thomas, National Center for Advancing Translational Sciences, Rockville, Maryland*
Jeanne Tie, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Samra Turajlic, The Francis Crick Institute, London, United Kingdom
Andreas S. Varkaris, MGH/Harvard Medical School, Boston, Massachusetts
Mike Waring, Northern Institute for Cancer Research, Newcastle upon Tyne, United Kingdom
Jing Wu, National Cancer Institute, Bethesda, Maryland
Oladapo Yeku, Massachusetts General Hospital, Boston, Massachusetts
Takayuki Yoshino, National Cancer Center Hospital East, Kashiwa City, Japan

* – denotes Executive Committee Member